Literature DB >> 28769467

DRUG THERAPY OF CYTOMEGALOVIRUS INFECTIONS.

S Shankar1, P C Sanchetee2.   

Abstract

Year:  2017        PMID： 28769467      PMCID： PMC5530887          DOI： 10.1016/S0377-1237(17)30689-5

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN： 0377-1237


× No keyword cloud information.
  9 in total

Review 1.  Cytomegalovirus and the peripheral nervous system in AIDS.

Authors:  G N Fuller
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

2.  Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia.

Authors:  D W Hecht; D R Snydman; C S Crumpacker; B G Werner; B Heinze-Lacey
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

Review 3.  Ganciclovir.

Authors:  C S Crumpacker
Journal:  N Engl J Med       Date:  1996-09-05       Impact factor: 91.245

4.  High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.

Authors:  N Singh; V L Yu; L Mieles; M M Wagener; R C Miner; T Gayowski
Journal:  Ann Intern Med       Date:  1994-03-01       Impact factor: 25.391

5.  Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial.

Authors:  D F Martin; D J Parks; S D Mellow; F L Ferris; R C Walton; N A Remaley; E Y Chew; P Ashton; M D Davis; R B Nussenblatt
Journal:  Arch Ophthalmol       Date:  1994-12

6.  Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1996-01

7.  Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.

Authors: 
Journal:  N Engl J Med       Date:  1992-01-23       Impact factor: 91.245

8.  Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients.

Authors:  R D Anderson; K G Griffy; D Jung; A Dorr; J D Hulse; R B Smith
Journal:  Clin Ther       Date:  1995 May-Jun       Impact factor: 3.393

9.  Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.

Authors:  S A Spector; G F McKinley; J P Lalezari; T Samo; R Andruczk; S Follansbee; P D Sparti; D V Havlir; G Simpson; W Buhles; R Wong; M Stempien
Journal:  N Engl J Med       Date:  1996-06-06       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.